Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?

American Journal of Pathology

Volumn 175, Issue 4, 2009, Pages 1389-1397

  Elsberger, Beatrix ^a   Tan, Bingchao A ^a   Mitchell, Thomas J ^a   Brown, Sylvia B F ^a   Mallon, Elizabeth A ^b   Tovey, Sian M ^a   Cooke, Timothy G ^a   Brunton, Valerie G ^c   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

EID: 73549112454     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090273     Document Type: Article

References (20)

1. Frame MC: Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002, 1602:114-130
2. Ito Y, Kawakatsu H, Takeda T, Tani N, Kawaguchi N, Noguchi S, Sakai T, Matsuura N: Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res Treat 2002, 76:261-267
3. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ: Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 2006, 95:1410-1414
4. Tice DA, Biscardi JS, Nickles AL, Parsons SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 1999, 96:1415-1420
5. Muthuswamy SK, Muller WJ: Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene 1995, 11:1801-1810
6. Landgren E, Blume-Jensen P, Courtneidge SA, Claesson-Welsh L: Fibroblast growth factor receptor-1 regulation of Src family kinases. Oncogene 1995, 10:2027-2035
7. Stover DR, Furet P, Lydon NB: Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J Biol Chem 1996, 271:12481-12487
8. Nigg EA, Sefton BM, Hunter T, Walter G, Singer SJ: Immunofluorescent localization of the transforming protein of Rous sarcoma virus with antibodies against a synthetic src peptide. Proc Natl Acad Sci USA 1982, 79:5322-5326
9. Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, Baba HA: High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome. Breast Cancer Res 2005, 7:R194-R203
10. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G: c-Src protein expression is increased in human breast cancer: an immunohistochemical and biochemical analysis J Pathol 1996, 180:383-388
11. Mamidipudi V, Dhillon NK, Parman T, Miller LD, Lee KC, Cartwright CA: RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene 2007, 26:2914-2924
12. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005, 11:4835-4842
13. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM: Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006, 48:787-794
14. Hynes NE: Tyrosine kinase signalling in breast cancer: Breast Cancer Res 2000, 2:154-157
15. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N: Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 1987, 84:2251-2255
16. Masaki T, Okada M, Shiratori Y, Rengifo W, Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, Omata M: pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 1998, 27:1257-1264
17. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple- negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007, 105:319-326
18. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R: Heregulin and HER2 signalling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 2003, 543:76-80
19. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244
20. Frame MC, Fincham VJ, Carragher NO, Wyke JA: v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002, 3:233-245